Pharming (PHAR) Net Income towards Common Stockholders (2019 - 2025)
Historic Net Income towards Common Stockholders for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $22.3 million.
- Pharming's Net Income towards Common Stockholders rose 9508.5% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.6 million, marking a year-over-year increase of 444.68%. This contributed to the annual value of -$233.0 million for FY2024, which is 463.71% down from last year.
- Per Pharming's latest filing, its Net Income towards Common Stockholders stood at $22.3 million for Q3 2025, which was up 9508.5% from -$10.0 million recorded in Q2 2025.
- Over the past 5 years, Pharming's Net Income towards Common Stockholders peaked at $22.3 million during Q3 2025, and registered a low of -$227.2 million during Q4 2024.
- For the 5-year period, Pharming's Net Income towards Common Stockholders averaged around -$106.7 million, with its median value being -$174.9 million (2021).
- Per our database at Business Quant, Pharming's Net Income towards Common Stockholders skyrocketed by 25133.09% in 2021 and then crashed by 10873166.02% in 2022.
- Quarter analysis of 5 years shows Pharming's Net Income towards Common Stockholders stood at $15.0 million in 2021, then tumbled by 1427.92% to -$199.1 million in 2022, then dropped by 13.32% to -$225.6 million in 2023, then decreased by 0.68% to -$227.2 million in 2024, then soared by 109.8% to $22.3 million in 2025.
- Its last three reported values are $22.3 million in Q3 2025, -$10.0 million for Q2 2025, and -$14.7 million during Q1 2025.